Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | Director | January 10, 2023 | February 24, 2023 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 06, 2021 | May 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date January 10, 2023 · Filed February 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 171,027 |
Reported balance
After 2023-01-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-10 · Exercise / conversion · Acquired 22,027 · Balance 171,027 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: On January 10, 2022, the Reporting Person was granted 81,082 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the anniversary of the grant date of January 10, 2022. F3: Not applicable. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 59,055 |
Reported balance
After 2023-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-10 · Exercise / conversion · Disposed 22,027 · Balance 59,055 F4: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2: On January 10, 2022, the Reporting Person was granted 81,082 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the anniversary of the grant date of January 10, 2022. F3: Not applicable. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: On January 10, 2022, the Reporting Person was granted 81,082 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the anniversary of the grant date of January 10, 2022.
F3: Not applicable.
F4: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
GILEAD SCIENCES, INC.
Report date May 06, 2021 · Filed May 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,060 |
Reported balance
After 2021-05-06 transaction · row 1
1 source rowRow 1 · 2021-05-06 · Exercise / conversion · Acquired 1,936 · Balance 102,060 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-06 · Exercise / conversion · Disposed 1,936 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: 100% of the restricted stock units vested on May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: 100% of the restricted stock units vested on May 6, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2013 Filed May 10, 2013 23:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 8,442 | $0.00 Strike: $52.38 | $0.00 |
DisclosureSEC source: 0001179110-13-008236 · edgar.xml · derivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,442 Underlying: Common Stock · 8,442 shares Expires 2023-05-08 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 20:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | PurchaseCommon Stock | 10,000 | $43.05 | $430,493.00 |
DisclosureSEC source: 0001179110-13-003984 · edgar.xml · nonDerivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,458 F1 · price: Purchase prices reported for the transactions reported here range from $43.04 to $43.05. Full information regarding the number of shares purchased at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 12, 2012 Filed May 16, 2012 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008468 · edgar.xml · derivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,926 Underlying: Common Stock · 3,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 12, 2012, at the end of the first year of service. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2012 Filed May 16, 2012 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008468 · edgar.xml · nonDerivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-008425 · edgar.xml · derivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,558 Underlying: Common Stock · 2,926 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 8,161 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001179110-12-008425 · edgar.xml · derivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,161 Underlying: Common Stock · 8,161 shares Expires 2022-05-10 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 10, 2013. Read SEC document |
| February 22, 2012 Filed Feb 23, 2012 20:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | PurchaseCommon Stock | 10,000 | $44.00 | $439,955.00 |
DisclosureSEC source: 0001179110-12-003320 · edgar.xml · nonDerivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,097 F1 · price: Purchase prices reported for the transactions reported here range from $43.99 to $44.00. Full information regarding the number of shares purchased at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-007994 · edgar.xml · derivative · entry 4 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,632 Underlying: Common Stock · 3,632 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,141 | $0.00 Strike: $41.29 | $0.00 |
DisclosureSEC source: 0001179110-11-007994 · edgar.xml · derivative · entry 3 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,141 Underlying: Common Stock · 10,141 shares Expires 2021-05-11 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 12, 2012. Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007994 · edgar.xml · derivative · entry 5 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,146 | $40.77 | $46,722.42 |
DisclosureSEC source: 0001179110-11-007994 · edgar.xml · nonDerivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,097 Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007994 · edgar.xml · nonDerivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 28, 2011 Filed Feb 2, 2011 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-001631 · edgar.xml · derivative · entry 3 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 890 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · derivative.exercise_date: Awards vest 100% on January 28, 2011. F1 · derivative.expiration_date: Awards vest 100% on January 28, 2011. Read SEC document |
| January 28, 2011 Filed Feb 2, 2011 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 267 | $38.21 | $10,202.07 |
DisclosureSEC source: 0001179110-11-001631 · edgar.xml · nonDerivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,423 Read SEC document |
| January 28, 2011 Filed Feb 2, 2011 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-001631 · edgar.xml · nonDerivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008585 · edgar.xml · derivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,820 Underlying: Common Stock · 3,820 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,860 | $0.00 Strike: $39.26 | $0.00 |
DisclosureSEC source: 0001179110-10-008585 · edgar.xml · derivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,860 Underlying: Common Stock · 10,860 shares Expires 2020-05-11 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 11, 2011. Read SEC document |
| May 04, 2010 Filed May 5, 2010 18:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | PurchaseCommon Stock | 8,704 | $38.60 | $335,974.40 |
DisclosureSEC source: 0001179110-10-007906 · edgar.xml · nonDerivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Read SEC document |
| May 04, 2010 Filed May 5, 2010 18:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | PurchaseCommon Stock | 4,096 | $38.59 | $158,064.64 |
DisclosureSEC source: 0001179110-10-007906 · edgar.xml · nonDerivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,096 Read SEC document |
| January 28, 2010 Filed Jan 29, 2010 02:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-001642 · edgar.xml · derivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890 Underlying: Common Stock · 890 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on January 28, 2011, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on January 28, 2011, at the end of the first year of service. Read SEC document |
| January 28, 2010 Filed Jan 29, 2010 02:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 2,454 | $0.00 Strike: $47.51 | $0.00 |
DisclosureSEC source: 0001179110-10-001642 · edgar.xml · derivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454 Underlying: Common Stock · 2,454 shares Expires 2020-01-28 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on January 28, 2011. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.